Andelyn Biosciences

The page covers considerations for AAV analytics in clinical program development, gene therapy manufacturing, and regulatory compliance.

The page describes how Andelyn Biosciences' AAV Curator platform supports gene therapy manufacturing and reduces the cost of goods sold (COGS) for advanced therapies.

The AAV manufacturing process plays a vital role in gene therapy, enabling efficient delivery of genetic material to combat diseases and genetic disorders.

Explore Andelyn Biosciences' advanced plasmid capabilities for viral vector production, enabling high-quality gene therapy development and manufacturing.

Andelyn Biosciences is a CDMO rooted in gene therapy research and works on manufacturing advances for the development of genetic medicines.

Andelyn Biosciences publishes news articles about its announcements and developments.

Andelyn Biosciences offers a comprehensive benefits package supporting employees' health, well-being, and work-life balance.

Andelyn Biosciences works on cell and gene therapy advancements.

Adam has experience in operational finance, technical accounting, procurement, information technology, legal matters, and corporate leadership, with expertise in growth and capitalization strategies for small businesses. Adam began a career at Deloitte’s Chicago assurance practice and joined a Wisconsin company in 2010, helping oversee its growth into the global CDMO Alcami Corporation.

Alex Fischer is president and CEO of the Columbus Partnership, a civic organization founded in 2002 for Columbus, Ohio, business leaders to improve Central Ohio’s economic and cultural base. The Partnership helps lead the One Columbus economic development effort and is involved in education reform with Columbus City Schools.

Andrew oversees process development and preclinical plasmid and viral vector production at Andelyn. He leads interdisciplinary scientists developing new vector production platforms and offering solutions to help clients accelerate gene therapy products.

Anu Bhatia is a senior member of Danaher Corporation’s (DHR) Corporate Development team, responsible for leading mergers and acquisitions, divestitures, minority investments, and strategic partnerships for Danaher and its operating companies. Before joining Danaher in 2020, Anu served as a strategic and financial advisor to companies and financial sponsors in the life sciences, diagnostics, medtech, and healthcare sectors as part of EY-Parthenon / Ernst and Y.

Andelyn Biosciences was formed from gene therapy breakthroughs at Nationwide Children's Hospital and works in development and contract development and manufacturing (CDMO).

Trace Andelyn Biosciences' journey from Nationwide Children’s Hospital's gene therapy innovations to a leading CDMO, shaping the future of medical treatments.

The name “Andelyn Biosciences” represents a hybrid of the name of two gene therapy pioneering patients.

Andelyn Biosciences offers services.

Andelyn Biosciences provides gene therapy CDMO services.

Explore Andelyn Biosciences' commitment to data privacy, outlining the handling and protection of personal information across their services and interactions.